On Oct. 22, Roche reported 7% growth at constant exchange rates (8% pharma, 5% diagnostics) in the third quarter, and management maintained full-year guidance for mid-single-digit sales and high-single-digit core EPS growth, also at constant rates. Shares traded flat.
Roche and its innovative US arm Genentech have a solid history of generating blockbuster therapies in oncology, and Roche's pipeline is full of novel candidates, with a particularly large late-stage pipeline.
Roche's immuno-oncology drug Tecentriq was launched third to market behind Bristol's Opdivo and Merck's Keytruda, raising questions about Roche's innovation.
|
Metric
|
ROP
|
MRK
|
ABBV
|
|---|---|---|---|
Price/Earnings (Normalized) | 21.96 | 165.74 | 27.13 |
Price/Book Value | 9.83 | 8.80 | — |
Price/Sales | 5.16 | 5.49 | 7.92 |
Price/Cash Flow | 16.15 | 16.74 | 22.38 |
|
Metric
|
ROP
|
MRK
|
ABBV
|
|---|---|---|---|
Quick Ratio | 0.80 | 0.71 | 0.49 |
Current Ratio | 1.23 | 1.32 | 0.81 |
Interest Coverage | 13.49 | 4.28 | 3.89 |
|
Metric
|
ROP
|
MRK
|
ABBV
|
|---|---|---|---|
Return on Assets (Normalized) | 15.81% | — | 14.29% |
Return on Equity (Normalized) | 48.77% | — | — |
Return on Invested Capital (Normalized) | 23.90% | — | 32.02% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| LOCK|HhJ<CS&! | LOCK|#g! | $1T | |||
| Johnson & Johnson
JNJ
| LOCK|?wdPq#> | LOCK|R^? | $658B | |||
| AbbVie Inc
ABBV
| LOCK|kp^!JD | LOCK|l> | $521B | |||
| Roche Holding AG ADR
RHHBY
| LOCK|<dN@$b%s | LOCK|M$W | $391B | |||
| Merck & Co Inc
MRK
| LOCK|R^!pk^D | LOCK|k^# | $369B | |||
| Novartis AG ADR
NVS
| LOCK|H&@jCLp? | LOCK|H!# | $307B | |||
| AstraZeneca PLC
AZN
| LOCK|$LR#$ND | LOCK|Gp^ | $290B | |||
| Amgen Inc
AMGN
| LOCK|Sdm>&M^ | LOCK|lF | $252B | |||
| Gilead Sciences Inc
GILD
| LOCK|N#Nl?<M | LOCK|!< | $212B | |||
| Novo Nordisk AS ADR
NVO
| LOCK|TT&hk>n | LOCK|@G& | $176B |
United States